HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the company has been selected to be added to the S&P SmallCap 600® Index at the close of trading on Tuesday, April 24, 2012. Following this addition, the Company will be a component of the NASDAQ Biotechnology Index®, the Russell 3000®, Russell 2000®, Russell Global® and S&P SmallCap 600® indices.
